Expression of survivin in invasive pituitary adenoma

Saudi Medical Journal

Volumn 29, Issue 11, 2008, Pages 1589-1592

  Zhang, Yong Chao ^a   Gao, Jun ^a   Xin, Tao ^a   Zheng, Zhi Ming ^a   Teng, Liang Zhu ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

SURVIVIN; BIRC5 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRAIN SURGERY; CANCER INVASION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; PROTEIN EXPRESSION; ADENOMA; HYPOPHYSIS TUMOR; METABOLISM; MIDDLE AGED;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; PITUITARY NEOPLASMS;

EID: 58949084965     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Laws ER Jr, Scheithauer BW, Carpenter S, Randall RV, Abboud CF. The pathogenesis of acromegaly: Clinical and immunocytochemical analysis in 75 patients. J Neurosurg 1985; 63: 35-38.
2. Randall RV, Laws ER Jr, Abboud CF, Ebersold MJ, Kao PC, Scheithauer BW. Transsphenoidal microsurgical treatment of prolactin-producing pituitary adenomas: Results in 100 patients. Mayo Clin Proc 1983; 58: 108-121.
3. Gürlek A: Karavitaki N, Ansorge O, Wass JA. What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. Eur J Endocrinol 2007; 156: 143-153.
4. Salvesen GS, Duckett CS. IAP proteins: Blocking the road to deaths door. Nat Rev Mol Cell Biol 2002; 3: 401-410. Review
5. Takai N, Miyazaki T, Nishida M, Nasu K, Miyikawa I. Survivin expression correlates with clinical stage, histological grade, invasive behavior, and survival rate in endometrial carcinoma. Cancer Lett 2002; 184: 105-116.
6. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396: 580-584.
7. Adida G, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 1998; 152: 43-49.
8. Lu CD, Altieri DC, Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 1998; 58: 1808-1812.
9. Montorsi M, Maggioni M, Falleni M, Pellegrini C, Donadon M. Torzilli G, et al. Survivin gene expression in chronic liver disease and hepatocellular carcinoma. Hepatogastroenterology 2007; 54: 2040-2044.
10. Shariat SF, Lotan Y, Saboorian H, Khoddami SM, Roehrborn CG, Slawin KM, et al. Survivin gene expression is associated with features of biologically aggressive prostate carcinoma. Cancer 2004; 100: 751-757.
11. Thomas S, Muralidharan A, Shah GV. Knock-down of calcitonin receptor expression induces apoptosis and growth arrest of prostate cancer cells. Int J Oncol 2007; 31: 1425-1437.
12. Wasko R, Jankowska A, Waligorska-Stachura J, Andrusiewicz M, Jaskula M, Sowinski J. Survivin expression in pituitary adenomas. Neuro Endocrinol Lett 2005; 26: 209-211.
13. Abe T, Lüdecke DK. Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol 2001; 145: 137-145.
14. Lüdecke DK, Flitsch J, Knappe UJ, Saeger W. Cushing's disease: A surgical view. J Neurooncol 2001; 54: 151-166. Review
15. Saeger W, Schröder S, Klöppel G. Pathology of important disease of endocrine organs (excluding the thyroid), Pathologe 2001; 22: 296-309.
16. Solcia E, Klöppel G, Sobin LH, Capella C, Lells RA de, Heitz PU, et al. International histological classification of tumors. In: Solcia E, Kloppel G, Sobin LH, editors. Histological typing of endocrine tumors. 2nd ed. Berlin, Heidelberg, New York: Springer; 2000. p. 1-149.
17. LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998; 17: 3247-3259.
18. Reed JC, The survivin goes in vivo. J Clin Inves 2001; 108: 965-969.
19. Geske FJ, Gerschenson LE. The biology of apoptosis. Hum Pathol 2001; 32: 1029-1038.
20. Saikumar P, Dong Z, Mikhailov V, Denton M, Weinberg JM, Venkatachalam MA. Apoptosis: Definition, mechanisms, and relevance to disease. Am J Med 1999; 107: 489-506.
21. Deveraux QL, Reed JC. IAP family proteins - suppressors of apoptosis. Genes Dev 1999; 13: 239-252. Review
22. Pennati M, Folini M,, Zaffaroni N. Targeting survivin in cancer therapy. Expert Opin Ther Targets 2008; 12: 463-476.
23. Kappler M, Rot S, Taubert H, Greither T, Bartel F, Dellas K, et al. The effects of knockdown of wild-type survivin, survivin-2B or survivin-delta3 on the radiosensitization in a soft tissue sarcoma cells in vitro under different oxygen conditions. Cancer Gene Ther 2007; 14: 994-1001.
24. Takizawa BT, Uchio EM, Cohen JJ, Wheeler MA, Weiss RM. Downregulation of survivin is associated with reductions in TNF receptors' mRNA and protein and alterations in nuclear factor kappa B signaling in urothelial cancer cells. Cancer Invest 2007; 25: 678-684.
25. Zhen HN, Li LW, Zhang W, Fei Z, Shi CH, Yang TT, et al. Short hairpin RNA targeting survivin inhibits growth and angiogenesis of glioma U251 cells. Int J Oncol 2007, 31: 1111-1117.